Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
Abstract Background Inosine pranobex (Isoprinosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of inosine pranobex versus placebo in subjects with clinically diagnosed influenza-like illness, including...
Main Authors: | Jiří Beran, Eva Šalapová, Marian Špajdel, on behalf of the Isoprinosine Study (EWO ISO-2014/1) Team |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2016-11-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12879-016-1965-5 |
Similar Items
-
Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes
by: Lasek Witold, et al.
Published: (2015-06-01) -
Genotoxicity and mutagenicity of inosine pranobex
by: Tobólska Sylwia, et al.
Published: (2018-07-01) -
Influence of inosine pranobex on cell viability in normal fibroblasts and liver cancer cells
by: Tobólska Sylwia, et al.
Published: (2018-07-01) -
Human papillomavirus infection: the efficacy of treatment with inosine pranobex
by: P V Budanov, et al.
Published: (2015-12-01) -
Use of inosine pranobex in frequently ill children
by: V. N. Drozdov, et al.
Published: (2019-11-01)